Literature DB >> 7516780

Treatment of renal calcium stone disease with the synthetic glycosaminoglycan pentosan polysulphate.

B Fellström1, U Backman, B Danielson, B Wikström.   

Abstract

Glycosaminoglycans (GAGs) are potent inhibitors of calcium oxalate growth and aggregation. The synthetic GAG pentosan polysulphate (PPS) was used in the treatment of patients with renal calcium stone disease. Altogether, 121 patients were included in an open trial over a 3-year-period. The average stone episode rate and the stone operation rate were no different during treatment and in the pretreatment period. Altogether 48% of the patients were entirely stone-free during follow-up, whereas 29/56 patients who continued to form stones reported smaller stones that were more easily passed. It is concluded that there may be a role for PPS in the treatment of recurrent renal calcium stone disease, but a controlled study may be needed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516780     DOI: 10.1007/bf00182052

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  7 in total

1.  Crystal inhibition: the effects of polyanions on calcium oxalate crystal growth.

Authors:  B Fellström; B G Danielson; S Ljunghall; B Wikström
Journal:  Clin Chim Acta       Date:  1986-08-15       Impact factor: 3.786

Review 2.  Inhibitors and promoters of stone formation.

Authors:  H Fleisch
Journal:  Kidney Int       Date:  1978-05       Impact factor: 10.612

3.  Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro.

Authors:  W G Robertson; M Peacock; B E Nordin
Journal:  Clin Chim Acta       Date:  1973-01-10       Impact factor: 3.786

4.  The acid mucopolysaccharides in normal urine.

Authors:  D P Varadi; J A Cifonelli; A Dorfman
Journal:  Biochim Biophys Acta       Date:  1967-06-13

5.  Binding of glycosaminoglycan inhibitors to calcium oxalate crystals in relation to ionic strength.

Authors:  B Fellström; M Lindsjö; B G Danielson; F A Karlsson; S Ljunghall
Journal:  Clin Chim Acta       Date:  1989-04-14       Impact factor: 3.786

6.  Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract.

Authors:  W G Robertson; M Peacock; R W Marshall; D H Marshall; B E Nordin
Journal:  N Engl J Med       Date:  1976-01-29       Impact factor: 91.245

7.  The nature of the non-ultrafilterable glycosaminoglycans of normal human urine.

Authors:  E Wessler
Journal:  Biochem J       Date:  1971-04       Impact factor: 3.857

  7 in total
  4 in total

1.  Characterization of glycosaminoglycans by 15N NMR spectroscopy and in vivo isotopic labeling.

Authors:  Vitor H Pomin; Joshua S Sharp; Xuanyang Li; Lianchun Wang; James H Prestegard
Journal:  Anal Chem       Date:  2010-05-15       Impact factor: 6.986

2.  Influence of sodium pentosan polysulphate and certain inhibitors on calcium oxalate crystal growth.

Authors:  D Senthil; K Subha; N Saravanan; P Varalakshmi
Journal:  Mol Cell Biochem       Date:  1996-03-09       Impact factor: 3.396

3.  Molecular size affects urine excretion of pentosan polysulfate.

Authors:  Deborah R Erickson; Mostafa Sheykhnazari; Veer P Bhavanandan
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

4.  Stabilization of submicron calcium oxalate suspension by chondroitin sulfate C may be an efficient protection from stone formation.

Authors:  Jun-Jun Li; Jun-Fa Xue; Jian-Ming Ouyang
Journal:  Bioinorg Chem Appl       Date:  2013-12-08       Impact factor: 7.778

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.